临床试验/NCT06303570

NCT06303570进行中（未招募）2 期

A Single-Blind, Placebo-Control, Randomized Phase 2 Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Caliway Biopharmaceuticals Co., Ltd.2 个研究点分布在 1 个国家目标入组 19 人开始时间: 2024年11月27日最近更新: 2026年4月14日

适应症

干预措施

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方: Caliway Biopharmaceuticals Co., Ltd.
入组人数: 19
试验地点: 2
主要终点: To estimate the treatment effect, as measured by pain, between CBL-514 and placebo in participants with DD.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.

详细描述

This is a phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's disease lipomas.

A total of approximately 25 participants will be randomized. Eligible participants will be randomized (1:1) to receive either CBL-514 or placebo once every 4 weeks for up to 5 treatments for each selected lipoma. Participant numbers are expected to be approximately balanced in each dose group (CBL-514 group and placebo group). Eligible participants must have at least 4 and up to 10 painful individual lipomas. The injection volume per lipoma will depend on the lipoma size (as determined by ultrasound).

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Single (Participant)

入排标准

年龄范围: 18 Years 至 64 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female, aged 18 years to 64 years old (at screening), inclusive.
•Body mass index (BMI) >18.5 kg/m2 at screening and Day
•Has confirmed DD and/or fulfills the following clinical criteria of DD in localized nodular form. The final diagnosis of disease is in the opinion of the Investigator.
•Chronic pain (>3 months) in the adipose tissue specific to the presence of lipomas and/or
•Pain in and around multiple lipomas.
•Has at least 4 and up to 10 painful and well-defined lipomas with dimension of ≥10 mm and ≤50 mm as measured by ultrasound (read by the Investigator) at screening.
•Generally considered healthy according to medical history, physical examination, ECG, and laboratory evaluation.
•Voluntarily signs the informed consent form (ICF) and, in the opinion of the Investigator or designee, is physically and mentally capable of participating in the study, and willing to adhere to study procedures.

排除标准

•Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive regimen from the time of screening and throughout study participation until 90 days after the last IP dose, or who is currently pregnant or lactating. Female participant of childbearing potential who is breastfeeding or anticipates breastfeeding from the time of screening and throughout study participation until 90 days after the last IP dose. Male participant who is not willing to commit to using of a condom and refraining from sperm donation from the time of the first dose of IP, throughout study participation until 90 days after the last IP dose.
•Unable to tolerate SC injections.
•Diagnosed with another disorder with similar characteristics as DD as follows.
•Madelung's disease: multiple symmetric lipomatosis only localized in the upper body ie, shoulders, neck, or head.
•Panniculitis: inflammation of the SC adipose tissue, characterized by tender nodules and systemic signs.
•Proteus syndrome: disproportionate and asymmetric overgrowth of skin, and fatty and connective tissue.
•PTEN hamartoma syndrome: multiple hamartomas which includes segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevus.
•Gardner syndrome: multiple digestive adenomas with osteomas and multiple skin and soft tissue tumors.
•Diagnosed with coagulation disorders or is receiving anticoagulant/antiplatelet therapy or medications or dietary supplements, which inhibit coagulation or platelet aggregation.
•Has fasting glucose concentration >200 mg/dL, delayed wound healing, bleeding risk, or any diabetic risks which, in the opinion of the Investigator or designee, is inappropriate to participate in the study.
•Any clinically significant cardiac, hepatic, renal or neurologic/psychiatric disorders that in the opinion of the Investigator places the participant at significant risk, including but not limited to any of the following:
•Participants with cirrhosis or with inadequate liver function at screening defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or total bilirubin >3.0 upper limit of normal (ULN).
•Participants with renal impairment, defined as both serum creatinine and blood urea nitrogen >1.5× ULN, or estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2, or who are currently on dialysis.
•Participant with a history of human immunodeficiency virus (HIV)-1 infection or participant with active HIV infection at screening with positive HIV antigen/antibody (Ag/Ab) combo test.
•Participant is undergoing chronic steroid or immunosuppressive therapy, with the exception of:
•Use of oral steroid inhalation indicated for asthma management
•Use of topical steroid application for skin conditions that are not directly applied to or indirectly affect the treatment area
•Use of steroid as part of treatment for DD, and no side effects from chornic use.
•Participant with active or prior history of malignancies within 5 years before screening or currently being evaluated for a possible malignancy, with the exception of adequately treated basal cell carcinoma of skin and in situ squamous cell carcinoma of skin at Investigator's discretion.
•Abnormal skin, local skin conditions, or body modifications at the treatment area, which in the opinion of the Investigator, is inappropriate for participation in the study, including but not limited to any of the following:
•Prior wound, scar tissue, or infection in the treated area.
•Tattoo in the treated area.
•Use of any analgesic except Cannabis within 2 days prior to Day 1 and use of Cannabis within 14 days prior to Day
•Requiring continual use of any medication that is known to strongly inhibit or induce CYP1A2 enzymes, sensitive CYP1A2 substrates or drugs with narrow therapeutic index during the study that, in the opinion of the Investigator, may affect the evaluation of the study product or place the participant at undue risk.
•Participant who has undergone liposuction or aesthetic surgery to the region to be treated before screening or during the study, or aesthetic procedure for body contouring (eg, cryolipolysis, ultrasonic lipolysis, low level laser therapy, lipolysis injection) to the region to be treated within 12 months before screening or during the study.
•Unable to receive local anesthesia.
•Known allergies or sensitivities to the study drug or its components.
•Use of other investigational drug or device within 12 weeks prior to screening.

研究组 & 干预措施

CBL-514 injection

Experimental

Eligible participants will receive CBL-514 administered in doses ranging from 1 mL to a maximum of 12 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.

干预措施: CBL-514 injection (Drug)

0.9% Sodium Chloride

Placebo Comparator

Eligible participants will receive 0.9% Sodium Chloride administered in doses ranging from 1 mL to a maximum of 12 mL per lipoma, with treatments scheduled at intervals of approximately 4 weeks, up to 5 treatments.

干预措施: 0.9% Sodium chloride (Drug)

结局指标

主要结局

To estimate the treatment effect, as measured by pain, between CBL-514 and placebo in participants with DD.

时间窗: Week 20

The Comparative Pain Scale is a 11-point scale (0-10) to assess pain from 0 being "pain free" to 10 being unimaginable/unspeakable pain.

To estimate the treatment effect, as measured by Partial Response (PR), between CBL-514 and placebo in participants with Dercum's disease (DD).

时间窗: Week 20

Lipoma volume will be determined by ultrasound assessment.

次要结局

To evaluate the incidence of adverse events of special interests (AESI) as defined in the protocol.(From baseline to 8 weeks post final treatment)
To evaluate the incidence of clinically significant abnormal findings as defined in the protocol as defined in the protocol.(From baseline to 8 weeks post final treatment)
To estimate the treatment effect, as measured by pain, between CBL-514 and placebo in participants with DD.(Up to 24 weeks)
To estimate the treatment effect, as measured by Partial Response (PR), between CBL-514 and placebo.(Up to 24 weeks)
To estimate the treatment effect, as measured by Partial Response (PR), between CBL-514 and placebo.(Week 24)
To assess the treatment effect, as measured by pain, between CBL-514 and placebo.(Up to 24 weeks)
To evaluate the incidence of adverse events of special interests (AESI) as defined in the protocol.(From baseline to 8 weeks post final treatment)
To evaluate the incidence of clinically significant abnormal findings as defined in the protocol as defined in the protocol.(From baseline to 8 weeks post final treatment)
To estimate the treatment effect, as measured by pain, between CBL-514 and placebo in participants with DD.(Week 20)
To estimate the treatment effect, as measured by Complete Response (CR), between CBL-514 and placebo.(Up to 24 weeks)
To evaluate the treatment effect, as measured by change in volume, between CBL-514 and placebo.(Up to 24 weeks)

研究者

发起方

Caliway Biopharmaceuticals Co., Ltd.

申办方类型

Industry

责任方

Sponsor

研究点 (2)

Loading locations...

相似试验

已完成

2 期

To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 ParticipantsCovid19

NCT04914377Novatek Pharmaceuticals55

终止

2 期

Efficacy and Safety Study of SUNPG1622Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis

NCT02980705Sun Pharmaceutical Industries Limited180

已完成

2 期

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)Acquired Thrombotic Thrombocytopenic Purpura

NCT01151423Ablynx, a Sanofi company75

已完成

2 期

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic PainSciatica

NCT00991172Regeneron Pharmaceuticals159

已完成

2 期

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTHealthy

NCT03288454Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.60